Acute Myeloid Leukemia Harboring the t(16;21)(p11;q22) Translocation Treated With Venetoclax Plus Azacitidine After Cord Blood Transplantation

A 62-year-old female was diagnosed with acute myeloid leukemia (AML) with t(16;21)(p11;q22). She achieved complete hematological remission after induction therapy and underwent umbilical cord blood stem cell transplantation (CBT). At 150 days after the CBT, a bone marrow examination revealed relapse...

Descripción completa

Detalles Bibliográficos
Autores principales: Teshima, Kazuaki, Ikeda, Sho, Abe, Ko, Yamada, Masahiro, Takahashi, Naoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439837/
https://www.ncbi.nlm.nih.gov/pubmed/37602052
http://dx.doi.org/10.7759/cureus.42215
_version_ 1785093039390195712
author Teshima, Kazuaki
Ikeda, Sho
Abe, Ko
Yamada, Masahiro
Takahashi, Naoto
author_facet Teshima, Kazuaki
Ikeda, Sho
Abe, Ko
Yamada, Masahiro
Takahashi, Naoto
author_sort Teshima, Kazuaki
collection PubMed
description A 62-year-old female was diagnosed with acute myeloid leukemia (AML) with t(16;21)(p11;q22). She achieved complete hematological remission after induction therapy and underwent umbilical cord blood stem cell transplantation (CBT). At 150 days after the CBT, a bone marrow examination revealed relapse. We treated the patient with venetoclax plus azacitidine as salvage therapy. After five cycles of venetoclax and azacitidine therapy, the patient died due to disease progression. The prognosis of AML with t(16;21)(p11;q22) is very poor owing to the high rate of early relapse even after hematopoietic stem cell transplantation. Therefore, a novel therapeutic approach is required to improve patient outcomes.
format Online
Article
Text
id pubmed-10439837
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-104398372023-08-20 Acute Myeloid Leukemia Harboring the t(16;21)(p11;q22) Translocation Treated With Venetoclax Plus Azacitidine After Cord Blood Transplantation Teshima, Kazuaki Ikeda, Sho Abe, Ko Yamada, Masahiro Takahashi, Naoto Cureus Internal Medicine A 62-year-old female was diagnosed with acute myeloid leukemia (AML) with t(16;21)(p11;q22). She achieved complete hematological remission after induction therapy and underwent umbilical cord blood stem cell transplantation (CBT). At 150 days after the CBT, a bone marrow examination revealed relapse. We treated the patient with venetoclax plus azacitidine as salvage therapy. After five cycles of venetoclax and azacitidine therapy, the patient died due to disease progression. The prognosis of AML with t(16;21)(p11;q22) is very poor owing to the high rate of early relapse even after hematopoietic stem cell transplantation. Therefore, a novel therapeutic approach is required to improve patient outcomes. Cureus 2023-07-20 /pmc/articles/PMC10439837/ /pubmed/37602052 http://dx.doi.org/10.7759/cureus.42215 Text en Copyright © 2023, Teshima et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Teshima, Kazuaki
Ikeda, Sho
Abe, Ko
Yamada, Masahiro
Takahashi, Naoto
Acute Myeloid Leukemia Harboring the t(16;21)(p11;q22) Translocation Treated With Venetoclax Plus Azacitidine After Cord Blood Transplantation
title Acute Myeloid Leukemia Harboring the t(16;21)(p11;q22) Translocation Treated With Venetoclax Plus Azacitidine After Cord Blood Transplantation
title_full Acute Myeloid Leukemia Harboring the t(16;21)(p11;q22) Translocation Treated With Venetoclax Plus Azacitidine After Cord Blood Transplantation
title_fullStr Acute Myeloid Leukemia Harboring the t(16;21)(p11;q22) Translocation Treated With Venetoclax Plus Azacitidine After Cord Blood Transplantation
title_full_unstemmed Acute Myeloid Leukemia Harboring the t(16;21)(p11;q22) Translocation Treated With Venetoclax Plus Azacitidine After Cord Blood Transplantation
title_short Acute Myeloid Leukemia Harboring the t(16;21)(p11;q22) Translocation Treated With Venetoclax Plus Azacitidine After Cord Blood Transplantation
title_sort acute myeloid leukemia harboring the t(16;21)(p11;q22) translocation treated with venetoclax plus azacitidine after cord blood transplantation
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439837/
https://www.ncbi.nlm.nih.gov/pubmed/37602052
http://dx.doi.org/10.7759/cureus.42215
work_keys_str_mv AT teshimakazuaki acutemyeloidleukemiaharboringthet1621p11q22translocationtreatedwithvenetoclaxplusazacitidineaftercordbloodtransplantation
AT ikedasho acutemyeloidleukemiaharboringthet1621p11q22translocationtreatedwithvenetoclaxplusazacitidineaftercordbloodtransplantation
AT abeko acutemyeloidleukemiaharboringthet1621p11q22translocationtreatedwithvenetoclaxplusazacitidineaftercordbloodtransplantation
AT yamadamasahiro acutemyeloidleukemiaharboringthet1621p11q22translocationtreatedwithvenetoclaxplusazacitidineaftercordbloodtransplantation
AT takahashinaoto acutemyeloidleukemiaharboringthet1621p11q22translocationtreatedwithvenetoclaxplusazacitidineaftercordbloodtransplantation

Ejemplares similares